Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Aug 22, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-08-09

Reporting Person: KALAJIAN TONY T (SVP-Chief Accounting Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$1.94	2029-08-14	Common Stock (275000)		Direct

Footnotes

F1: 87,500 options will vest and become exercisable upon completion of one year of continuous service as an employee, and the balance of the options will vest in 36 equal monthly installments thereafter, subject to continued service as an employee on the applicable vesting date.